Resected oropharyngeal cancer: “no benefit” from intensified adjuvant therapy

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • Adjuvant chemoradiotherapy (CRT) and boost doses of postoperative radiotherapy (B-PORT) are not associated with improved overall survival of patients with oropharyngeal squamous cell carcinoma (OPSCC) treated with primary surgery.

Key results

  • CRT (HR, 1.27; 95% CI, 0.70-2.30) and B-PORT (HR, 1.04; 95% CI, 0.63-1.73) were not significantly associated with improved overall survival.
  • Human papillomavirus (HPV) positivity (HR, 0.41; 95% CI, 0.21-0.80), positive surgical margins (HR, 2.15; 95% CI, 1.27-3.66), and ≥6 involved nodes (HR, 2.11; 95% CI, 1.13-3.93) were significantly associated with overall survival.

Study design

  • 1409 patients with stage III to IVA-B OPSCC treated with primary surger...